Science Explorer Back to mapMap
Discussion
Company · Berkeley · United States

Carmot Therapeutics (United States)

carmot-therapeutics.usROR OpenAlex
Research works
14
▲ 6% vs 2018-21
Citations
920
68.0 per fractional work
Top-10% rate
37.1%
all institutions 10.0%
Open access
47%
world 40%
International
30%
world 18%
Carmot Therapeutics (United States)

Not ranked overall: Carmot Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Carmot Therapeutics (United States) work in?

In all years, 43% of research at Carmot Therapeutics (United States) is in Life Sciences, 28% in Physical Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (31%), Medicine (23%), Computer Science (14%). It does 1.7× the world's share of Life Sciences.

Life Sciences: 6 fractional works · 42.8% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 30.8% of its workMolecular Biology: 4 fractional works · 28.8% of its workGenetics: 0 fractional works · 2.0% of its workNeuroscience: 1 fractional works · 7.0% of its workCellular and Molecular Neuroscience: 1 fractional works · 6.5% of its workBiological Psychiatry: 0 fractional works · 0.5% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 5.0% of its workPharmacology: 1 fractional works · 5.0% of its workPhysical Sciences: 4 fractional works · 27.9% of its workComputer Science: 2 fractional works · 14.0% of its workComputational Theory and Mathematics: 2 fractional works · 14.0% of its workChemistry: 2 fractional works · 13.4% of its workPhysical and Theoretical Chemistry: 1 fractional works · 7.4% of its workOrganic Chemistry: 1 fractional works · 6.0% of its workMaterials Science: 0 fractional works · 0.6% of its workMaterials Chemistry: 0 fractional works · 0.6% of its workHealth Sciences: 3 fractional works · 25.6% of its workMedicine: 3 fractional works · 23.4% of its workPharmacology: 1 fractional works · 5.8% of its workEndocrinology, Diabetes and Metabolism: 1 fractional works · 4.1% of its workOncology: 0 fractional works · 3.5% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 2.7% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 1.8% of its workPulmonary and Respiratory Medicine: 0 fractional works · 1.3% of its workPsychiatry and Mental health: 0 fractional works · 1.1% of its workPhysiology: 0 fractional works · 0.8% of its workReproductive Medicine: 0 fractional works · 0.6% of its workSurgery: 0 fractional works · 0.6% of its workEpidemiology: 0 fractional works · 0.5% of its workOphthalmology: 0 fractional works · 0.4% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.3% of its workNursing: 0 fractional works · 1.4% of its workNutrition and Dietetics: 0 fractional works · 1.4% of its workHealth Professions: 0 fractional works · 0.8% of its workPharmacy: 0 fractional works · 0.8% of its workSocial Sciences: 0 fractional works · 3.7% of its workEconomics, Econometrics and Finance: 0 fractional works · 3.7% of its workEconomics and Econometrics: 0 fractional works · 3.7% of its workALL ITS WORKCarmotTherapeutics…14fractional works, all years
Life Sciences43%Physical Sciences28%Health Sciences26%Social Sciences4%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 10 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology430.8%
    2. Neuroscience17.0%
    3. Pharmacology, Toxicology and Pharmaceutics15.0%
    1. Computer Science214.0%
    2. Chemistry213.4%
    3. Materials Science00.6%
    1. Medicine323.4%
    2. Nursing01.4%
    3. Health Professions00.8%
    1. Economics, Econometrics and Finance03.7%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 2.13× its world share, 0 worksBiochemistry, Geneti…Neuroscience: 10.98× its world share, 1 worksNeuroscienceComputer Science: 0.93× its world share, 0 worksComputer ScienceHealth Professions: 1.22× its world share, 0 worksHealth ProfessionsMedicine: 3.01× its world share, 2 worksMedicineNursing: 4.93× its world share, 0 worksNursing1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Neuroscience, 11.0×. Every wedge is a field page.

All 6 fields, with their numbers
  1. Neuroscience10.98×1 works
  2. Nursing4.93×0 works
  3. Medicine3.01×2 works
  4. Biochemistry, Genetics and Molecular Biology2.13×0 works
  5. Health Professions1.22×0 works
  6. Computer Science0.93×0 works

What are the most cited papers from Carmot Therapeutics (United States)?

The most cited paper from Carmot Therapeutics (United States) is "Twenty years on: the impact of fragments on drug discovery" (Daniel A. Erlanson, Stephen W. Fesik, Roderick E. Hubbard et al., 2016), with 1,016 citations. Next come "Introduction to Fragment-Based Drug Discovery" (264) and "Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia" (238).

Most cited papers
#PaperReleasedCitations
1 Twenty years on: the impact of fragments on drug discovery Daniel A. Erlanson, Stephen W. Fesik, Roderick E. Hubbard et al. · Nature Reviews Drug Discovery Review 15 Jul 2016 1,016
2 Introduction to Fragment-Based Drug Discovery Daniel A. Erlanson · Topics in current chemistry Book chapter 2011 264
3 Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia György Miklós Keserű, Daniel A. Erlanson, György G. Ferenczy et al. · Journal of Medicinal Chemistry 28 Apr 2016 238
4 Learning from our mistakes: The ‘unknown knowns’ in fragment screening Ben J. Davis, Daniel A. Erlanson · Bioorganic & Medicinal Chemistry Letters Open access 18 Mar 2013 146
5 Validity of Ligand Efficiency Metrics Christopher W. Murray, Daniel A. Erlanson, Andrew L. Hopkins et al. · ACS Medicinal Chemistry Letters Open access 9 May 2014 138
All 26 most cited papers, with filters and sorting

Which research topics does Carmot Therapeutics (United States) publish most on?

By volume in 2022-now: Neuropeptides and Animal Physiology, Diabetes Treatment and Management, Pharmacology and Obesity Treatment and Biotechnology and Related Fields.

Neuropeptides and Animal Physiology: 0 fractional worksDiabetes Treatment and Management: 0 fractional worksPharmacology and Obesity Treatment: 0 fractional worksBiotechnology and Related Fields: 0 fractional worksComputational Drug Discovery Methods: 0 fractional worksVirus-based gene therapy…0Virus-based gene therapy research: 0 fractional worksSchizophrenia research and treatment: 0 fractional worksPluripotent Stem Cells Research: 0 fractional worksCAR-T cell therapy research: 0 fractional worksDiet and metabolism studies: 0 fractional works
Cellular and Molecular NeuroscienceEndocrinology, Diabetes and MetabolismPharmacologyPublic Health, Environmental and Occupational Health6 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Neuropeptides and Animal Physiology Cellular and Molecular Neuroscience 0 works
  2. 2 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 0 works
  3. 3 Pharmacology and Obesity Treatment Pharmacology 0 works
  4. 4 Biotechnology and Related Fields Public Health, Environmental and Occupational Health 0 works
  5. 5 Computational Drug Discovery Methods Computational Theory and Mathematics 0 works
  6. 6 Virus-based gene therapy research Genetics 0 works
  7. 7 Schizophrenia research and treatment Psychiatry and Mental health 0 works
  8. 8 Pluripotent Stem Cells Research Molecular Biology 0 works
  9. 9 CAR-T cell therapy research Oncology 0 works
  10. 10 Diet and metabolism studies Physiology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available47.1%not open52.9%

World: 40% of research is openly available.

with international co-authors30.4%domestic only69.6%

World: 18% is written across borders.

How has Carmot Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 6% higher than in 2018-2021.

still counting201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Carmot Therapeutics (United States) as a percentage of every work published that year, 0.0000036% in 2024.

still counting0.000020%0.000040%0.000060%Carmot Therapeutics (United States)0.000048% in 20252020

Fractional works of Carmot Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Berkeley

All research institutions in Berkeley

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Carmot Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.